Severe Asthma: An Update for 2019

Adam D. Highley, MD; Craig Cookman, DO; Lee E. Morrow, MD, FCCP, ATSF; Mark A. Malesker, PharmD, FCCP, FCCP, FCCM, FASHP, BCPS


US Pharmacist. 2019;44(7):HS 2-HS 7. 

In This Article


Asthma is a major chronic disease that affects individuals in all age groups. All patients with asthma are at risk for acute exacerbations. Pharmacists in all healthcare settings should be conversant with evidence-based pharmacotherapy for the management of acute exacerbations of and preventive therapy for severe asthma. Acute exacerbations are managed with inhaled bronchodilators, inhaled corticosteroids, and oral corticosteroids. Patient-specific pharmacotherapy to prevent acute exacerbations includes the use of inhaled corticosteroids, often in combination with a long-acting bronchodilator, a short-acting bronchodilator for rescue, a long-acting antimuscarinic antagonist, a leukotriene antagonist, and biologics. Biological therapies represent a treatment option for patients with severe asthma unresponsive or intolerant to traditional treatments.